PR Newswire BiotechOriginal article
Lynch Regenerative Medicine Announces Completion of Enrollment in a Phase II Clinical Trial Evaluating rhPDGF-BB in the Reconstruction of Full-Thickness Head or Neck Defects Following Skin Cancer Excision
Phase 2rhPDGF-BBPositive
AI Analysis
Summary
Lynch Regenerative Medicine announced completion of enrollment in a Phase II randomized, double-blinded, controlled clinical trial evaluating rhPDGF-BB for reconstruction of full-thickness head and neck defects following skin cancer excision.
Clinical Trial Data
Phase
II
Outcome Details
Enrollment completion announced
Importance:5/10
Sentiment:
0.30
Phase 2Clinical TrialEnrollment CompleteRegenerative MedicineWound Healing
Related Companies
Read the original article
Published by PR Newswire Biotech on August 18, 2026 12:45 PM